Catalyst Pharmaceuticals Inc

CPRX · Moat type: REGULIERUNG

MoatScore

9/10

Fair Value

52 USD

Margin of Safety

+39.4 %

Rating

STARK

GESCHÄFTSMODELL Catalyst Pharmaceuticals develops and markets prescription specialty pharmaceuticals for rare neuromuscular diseases, with its core product Firdapse (amifampridine) dominating revenue as an FDA-approved therapy for Lambert-Eaton myasthenic syndrome and protected by a strong regulatory and patent-backed competitive moat.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.